Optiscan Imaging Limited has entered into a three-year strategic collaboration agreement with Australian Clinical Labs Limited to accelerate the development and deployment of its InForm digital pathology platform.
In a statement, Optiscan said the agreement will support the validation of its InForm device within ACL’s laboratory network, allowing testing in real-world conditions and the collection of imaging data across a range of human tissues and pathologies.
The collaboration also aims to advance the company’s preparations for regulatory submissions in Australia and the United States, Optiscan said in an ASX announcement.
Under the partnership, Optiscan will test its InForm device at ACL’s flagship anatomical pathology laboratory in Western Australia.
The initiative is expected to build an image databank that will assist in pathologist training and support the integration of digital pathology workflows across the healthcare sector.
“This three-year Collaboration Agreement with ACL comes with two clear-cut advantages that make it a real game-changer in the broader development and ultimately commercialisation strategies for our InForm digital pathology device,” said Optiscan CEO and Managing Director, Dr Camile Farah.
“It gives us access to a fully operational pathology laboratory that will quicken the pace at which we validate the InForm device in real-world conditions, ensuring it meets the needs of healthcare sector professionals, pathologists and technicians.”
“Then there is the regulatory approvals-related advantage delivered by the Agreement. It will help expedite our plans to build an image databank of human tissues and associated pathologies, a useful data collection resource that will be incorporated into preparatory work we are now undertaking for regulatory submissions in Australia and in the US,” Dr Farah added.
He said the partnership marks a significant step towards the company’s goal of transforming pathology by enabling real-time digital microscopic insights at the point of care.
“Our stated goal has always been to revolutionise pathology by delivering real-time digital microscopic insights at point of care, and I want to personally thank ACL for sharing in this vision,” Dr Farah said.
“I am confident that this Agreement will deliver outcomes that demonstrate the significant efficiencies in pathology services encapsulated in our digital solution.”
ACL’s Medical Director and Chief Pathologist, Associate Professor Tony Landgren, said the collaboration aligns with the organisation’s focus on innovation and clinical advancement.
“We are excited to collaborate with Optiscan, highlighting our commitment to innovation and clinical excellence,” he said. “This opportunity has the potential to enhance diagnostic workflows with real-time, data-driven insights – a move that supports faster, more accurate decision-making.”
According to Optiscan, the collaboration represents a milestone in digital pathology by enabling end-to-end, real-time analysis of tissue samples at the point of contact.
The company said the partnership will also enhance ACL’s digital capabilities while accelerating Optiscan’s commercial readiness.
Both companies said they will provide updates as milestones are achieved throughout the duration of the collaboration.
The content of this article is based on information supplied by Optiscan Imaging Limited. For more information, please refer to the official company announcement and communications from Optiscan. Please consult a licensed and/or registered professional in this area before making any decisions based on the content of this article.
